Is omalizumab safe and effective in oncological patients?
A 42‐year‐old female with a personal history of Grade II infiltrating ductal breast carcinoma, treated under surgical procedure in 2018, whose hormonal profile included estrogen, progesteronic and HER‐2 positive receptors, and a Ki67 proliferative index (20–25%), was referred to our dermatological o...
Gespeichert in:
Veröffentlicht in: | Dermatologic therapy 2019-11, Vol.32 (6), p.e13115-n/a |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | n/a |
---|---|
container_issue | 6 |
container_start_page | e13115 |
container_title | Dermatologic therapy |
container_volume | 32 |
creator | Navarro‐Triviño, Francisco J. Mérida‐Fernández, Carolina Linares‐Gonzalez, Laura Ruiz‐Villaverde, Ricardo |
description | A 42‐year‐old female with a personal history of Grade II infiltrating ductal breast carcinoma, treated under surgical procedure in 2018, whose hormonal profile included estrogen, progesteronic and HER‐2 positive receptors, and a Ki67 proliferative index (20–25%), was referred to our dermatological outpatient clinic complaining worsening of her chronic spontaneous urticaria. The patient was under treatment with etuximide, exemestane, anastrozole, and trastuzumab. Our patient reported intermittent episodes of hives of 8 years of evolution with good control with second‐generation antihistamines. However, in the past year, the intensity and frequency of the outbreaks was increased with the development of angioedema until completing 23 consultations through the emergency department being treated in all of the episodes with short cycles of oral corticosteroids. This case reported is particularly complex due to different points that we develop below: (a) oncological patient as special population; (b) differential diagnosis with other forms of urticaria such as vasculitis urticaria, inducible urticaria, and autoimmune progesterone dermatitis; (c) spontaneous chronic urticaria of difficult control at labeled dose of omalizumab; (d) concomitant treatment with another biological drug. |
doi_str_mv | 10.1111/dth.13115 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2308520720</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2308520720</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3605-efe08cf8bbbe7f251fab9d32c22fca38bae29b6d084834f63f7282318665f9243</originalsourceid><addsrcrecordid>eNp1kDtPwzAURi0EoqUw8AdQRhjS-pE49oRQebRSJZYyW7ZzDUZ5ESeg8usJpLBxl-8OR2c4CJ0TPCfDLfLuZU4YIekBmpKUylhgIg-Hn0keYyr5BJ2E8IoxoZKRYzRhhCc8I3yK5DpEdakL_9mX2kRBO4h0lUfgHNjOv0Pkq6iubF3Uz97qImp056HqwvUpOnK6CHC23xl6ur_bLlfx5vFhvbzZxJZxnMbgAAvrhDEGMkdT4rSROaOWUmc1E0YDlYbnWCSCJY4zl1FBGRGcp07ShM3Q5eht2vqth9Cp0gcLRaErqPugKMMipTijeECvRtS2dQgtONW0vtTtThGsvkupoZT6KTWwF3ttb0rI_8jfNAOwGIEPX8Duf5O63a5G5Rf9XHFu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2308520720</pqid></control><display><type>article</type><title>Is omalizumab safe and effective in oncological patients?</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Navarro‐Triviño, Francisco J. ; Mérida‐Fernández, Carolina ; Linares‐Gonzalez, Laura ; Ruiz‐Villaverde, Ricardo</creator><creatorcontrib>Navarro‐Triviño, Francisco J. ; Mérida‐Fernández, Carolina ; Linares‐Gonzalez, Laura ; Ruiz‐Villaverde, Ricardo</creatorcontrib><description>A 42‐year‐old female with a personal history of Grade II infiltrating ductal breast carcinoma, treated under surgical procedure in 2018, whose hormonal profile included estrogen, progesteronic and HER‐2 positive receptors, and a Ki67 proliferative index (20–25%), was referred to our dermatological outpatient clinic complaining worsening of her chronic spontaneous urticaria. The patient was under treatment with etuximide, exemestane, anastrozole, and trastuzumab. Our patient reported intermittent episodes of hives of 8 years of evolution with good control with second‐generation antihistamines. However, in the past year, the intensity and frequency of the outbreaks was increased with the development of angioedema until completing 23 consultations through the emergency department being treated in all of the episodes with short cycles of oral corticosteroids. This case reported is particularly complex due to different points that we develop below: (a) oncological patient as special population; (b) differential diagnosis with other forms of urticaria such as vasculitis urticaria, inducible urticaria, and autoimmune progesterone dermatitis; (c) spontaneous chronic urticaria of difficult control at labeled dose of omalizumab; (d) concomitant treatment with another biological drug.</description><identifier>ISSN: 1396-0296</identifier><identifier>EISSN: 1529-8019</identifier><identifier>DOI: 10.1111/dth.13115</identifier><identifier>PMID: 31646716</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Adult ; Breast Neoplasms - drug therapy ; Carcinoma, Ductal, Breast - drug therapy ; Chronic Disease ; effectiveness ; Female ; Humans ; omalizumab ; Omalizumab - administration & dosage ; Omalizumab - adverse effects ; safety ; trastuzumab ; Urticaria - drug therapy</subject><ispartof>Dermatologic therapy, 2019-11, Vol.32 (6), p.e13115-n/a</ispartof><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3605-efe08cf8bbbe7f251fab9d32c22fca38bae29b6d084834f63f7282318665f9243</citedby><cites>FETCH-LOGICAL-c3605-efe08cf8bbbe7f251fab9d32c22fca38bae29b6d084834f63f7282318665f9243</cites><orcidid>0000-0002-5454-3671 ; 0000-0002-0381-6174</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdth.13115$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdth.13115$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31646716$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Navarro‐Triviño, Francisco J.</creatorcontrib><creatorcontrib>Mérida‐Fernández, Carolina</creatorcontrib><creatorcontrib>Linares‐Gonzalez, Laura</creatorcontrib><creatorcontrib>Ruiz‐Villaverde, Ricardo</creatorcontrib><title>Is omalizumab safe and effective in oncological patients?</title><title>Dermatologic therapy</title><addtitle>Dermatol Ther</addtitle><description>A 42‐year‐old female with a personal history of Grade II infiltrating ductal breast carcinoma, treated under surgical procedure in 2018, whose hormonal profile included estrogen, progesteronic and HER‐2 positive receptors, and a Ki67 proliferative index (20–25%), was referred to our dermatological outpatient clinic complaining worsening of her chronic spontaneous urticaria. The patient was under treatment with etuximide, exemestane, anastrozole, and trastuzumab. Our patient reported intermittent episodes of hives of 8 years of evolution with good control with second‐generation antihistamines. However, in the past year, the intensity and frequency of the outbreaks was increased with the development of angioedema until completing 23 consultations through the emergency department being treated in all of the episodes with short cycles of oral corticosteroids. This case reported is particularly complex due to different points that we develop below: (a) oncological patient as special population; (b) differential diagnosis with other forms of urticaria such as vasculitis urticaria, inducible urticaria, and autoimmune progesterone dermatitis; (c) spontaneous chronic urticaria of difficult control at labeled dose of omalizumab; (d) concomitant treatment with another biological drug.</description><subject>Adult</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Carcinoma, Ductal, Breast - drug therapy</subject><subject>Chronic Disease</subject><subject>effectiveness</subject><subject>Female</subject><subject>Humans</subject><subject>omalizumab</subject><subject>Omalizumab - administration & dosage</subject><subject>Omalizumab - adverse effects</subject><subject>safety</subject><subject>trastuzumab</subject><subject>Urticaria - drug therapy</subject><issn>1396-0296</issn><issn>1529-8019</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kDtPwzAURi0EoqUw8AdQRhjS-pE49oRQebRSJZYyW7ZzDUZ5ESeg8usJpLBxl-8OR2c4CJ0TPCfDLfLuZU4YIekBmpKUylhgIg-Hn0keYyr5BJ2E8IoxoZKRYzRhhCc8I3yK5DpEdakL_9mX2kRBO4h0lUfgHNjOv0Pkq6iubF3Uz97qImp056HqwvUpOnK6CHC23xl6ur_bLlfx5vFhvbzZxJZxnMbgAAvrhDEGMkdT4rSROaOWUmc1E0YDlYbnWCSCJY4zl1FBGRGcp07ShM3Q5eht2vqth9Cp0gcLRaErqPugKMMipTijeECvRtS2dQgtONW0vtTtThGsvkupoZT6KTWwF3ttb0rI_8jfNAOwGIEPX8Duf5O63a5G5Rf9XHFu</recordid><startdate>201911</startdate><enddate>201911</enddate><creator>Navarro‐Triviño, Francisco J.</creator><creator>Mérida‐Fernández, Carolina</creator><creator>Linares‐Gonzalez, Laura</creator><creator>Ruiz‐Villaverde, Ricardo</creator><general>John Wiley & Sons, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5454-3671</orcidid><orcidid>https://orcid.org/0000-0002-0381-6174</orcidid></search><sort><creationdate>201911</creationdate><title>Is omalizumab safe and effective in oncological patients?</title><author>Navarro‐Triviño, Francisco J. ; Mérida‐Fernández, Carolina ; Linares‐Gonzalez, Laura ; Ruiz‐Villaverde, Ricardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3605-efe08cf8bbbe7f251fab9d32c22fca38bae29b6d084834f63f7282318665f9243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Carcinoma, Ductal, Breast - drug therapy</topic><topic>Chronic Disease</topic><topic>effectiveness</topic><topic>Female</topic><topic>Humans</topic><topic>omalizumab</topic><topic>Omalizumab - administration & dosage</topic><topic>Omalizumab - adverse effects</topic><topic>safety</topic><topic>trastuzumab</topic><topic>Urticaria - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Navarro‐Triviño, Francisco J.</creatorcontrib><creatorcontrib>Mérida‐Fernández, Carolina</creatorcontrib><creatorcontrib>Linares‐Gonzalez, Laura</creatorcontrib><creatorcontrib>Ruiz‐Villaverde, Ricardo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Dermatologic therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Navarro‐Triviño, Francisco J.</au><au>Mérida‐Fernández, Carolina</au><au>Linares‐Gonzalez, Laura</au><au>Ruiz‐Villaverde, Ricardo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is omalizumab safe and effective in oncological patients?</atitle><jtitle>Dermatologic therapy</jtitle><addtitle>Dermatol Ther</addtitle><date>2019-11</date><risdate>2019</risdate><volume>32</volume><issue>6</issue><spage>e13115</spage><epage>n/a</epage><pages>e13115-n/a</pages><issn>1396-0296</issn><eissn>1529-8019</eissn><abstract>A 42‐year‐old female with a personal history of Grade II infiltrating ductal breast carcinoma, treated under surgical procedure in 2018, whose hormonal profile included estrogen, progesteronic and HER‐2 positive receptors, and a Ki67 proliferative index (20–25%), was referred to our dermatological outpatient clinic complaining worsening of her chronic spontaneous urticaria. The patient was under treatment with etuximide, exemestane, anastrozole, and trastuzumab. Our patient reported intermittent episodes of hives of 8 years of evolution with good control with second‐generation antihistamines. However, in the past year, the intensity and frequency of the outbreaks was increased with the development of angioedema until completing 23 consultations through the emergency department being treated in all of the episodes with short cycles of oral corticosteroids. This case reported is particularly complex due to different points that we develop below: (a) oncological patient as special population; (b) differential diagnosis with other forms of urticaria such as vasculitis urticaria, inducible urticaria, and autoimmune progesterone dermatitis; (c) spontaneous chronic urticaria of difficult control at labeled dose of omalizumab; (d) concomitant treatment with another biological drug.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>31646716</pmid><doi>10.1111/dth.13115</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-5454-3671</orcidid><orcidid>https://orcid.org/0000-0002-0381-6174</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1396-0296 |
ispartof | Dermatologic therapy, 2019-11, Vol.32 (6), p.e13115-n/a |
issn | 1396-0296 1529-8019 |
language | eng |
recordid | cdi_proquest_miscellaneous_2308520720 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Adult Breast Neoplasms - drug therapy Carcinoma, Ductal, Breast - drug therapy Chronic Disease effectiveness Female Humans omalizumab Omalizumab - administration & dosage Omalizumab - adverse effects safety trastuzumab Urticaria - drug therapy |
title | Is omalizumab safe and effective in oncological patients? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T11%3A31%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20omalizumab%20safe%20and%20effective%20in%20oncological%20patients?&rft.jtitle=Dermatologic%20therapy&rft.au=Navarro%E2%80%90Trivi%C3%B1o,%20Francisco%20J.&rft.date=2019-11&rft.volume=32&rft.issue=6&rft.spage=e13115&rft.epage=n/a&rft.pages=e13115-n/a&rft.issn=1396-0296&rft.eissn=1529-8019&rft_id=info:doi/10.1111/dth.13115&rft_dat=%3Cproquest_cross%3E2308520720%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2308520720&rft_id=info:pmid/31646716&rfr_iscdi=true |